Patients with severe haemophilia A receiving emicizumab will often need concomitant FVIII to provide haemostatic cover during major surgery. This prospective, open-label, uncontrolled, single-arm, multinational, multicentre study aims to evaluate the overall perioperative haemostatic efficacy of Nuwiq, a recombinant factor VIII, in combination with emicizumab prophylaxis in male patients over 12 with severe haemophilia A undergoing major surgery.
Age
12–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Severe haemophilia A (FVIII activity \[FVIII:C\] \<1%) according to medical history
Male patients at least 12 years of age
Previous treatment with any FVIII product(s) for at least 150 exposure days
On regular prophylaxis with emicizumab for at least 1 month prior to a scheduled major elective surgery requiring FVIII treatment
Freely given written informed consent of the patient, or parent/legal representative where applicable, obtained in accordance with local regulations
You may not be if
Coagulation disorder other than haemophilia A
Present or past FVIII inhibitor (≥0.6 Bethesda units \[BU\]/mL) according to medical history
Severe liver or kidney disease (alanine aminotransferase \[ALT\] and/or aspartate aminotransferase \[AST\] levels \>5 times the upper limit of normal; or creatinine \>120 μmol/L)
Known hypersensitivity to Nuwiq's active substance or its excipients (sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, poloxamer 188)
Already had surgery in this study
Current participation in another interventional clinical trial
Treatment with any investigational medicinal product (IMP) within 30 days prior to screening visit